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1. Introduction
Depigmentation, lightening of the skin and mucosa, can be caused by local 
or systemic conditions, and there may be partial or complete loss of pigment [1]. 
Although depigmented patches may not matter in Caucasians, it is very serious for 
pigmented skin [2]. Depigmentation can also be a therapeutic goal for cosmetic 
treatment. Many vitiligo patients, who received depigmentation treatment, 
experience paradoxical jealousy because of their clean white skin. To improve 
facial blemishes, many people spend their money for laser, chemical peel, and 
cosmeceutical [3, 4].
Depigmentation can occur hereditarily or acquiredly. Hereditary diseases if 
depigmentation includes following diseases  (Figure 1) [3]. Oculocutaneous albi-
nism consists of a group of genetic disorders characterized by diffuse pigmentary 
dilution due to a partial or total absence of melanin pigment within melanocytes 
of the skin and eyes. Piebaldism is an genetic disorder characterized by poliosis 
and congenital, stable, circumscribed areas of leukoderma due to an absence of 
melanocytes within involved sites. Waardenburg syndrome is a rare genetic dis-
ease characterized by various combinations of depigmentation of skin and irides, 
and congenital deafness. Hermansky–Pudlak syndrome is a rare genetic disease 
of depigmentation showing pigmentary dilution of the skin, hair, and eyes, and 
serious systemic manifestations including hematopoietic, immune, pulmonary, 
renal, and cardiac symptoms. Chédiak–Higashi syndrome is a rare genetic disorder 
showing features of oculocutaneous albinism, ocular symptoms, hematologic and 
neurologic manifestations. Tuberous sclerosis complex is an autosomal dominant 
disorder characterized by neuroligic disorders and skin findings including depig-
mented macules. Depigmentation along the lines of Blaschko reflects mosaicism 
characterized by a clone of skin cells with a decreased ability to make pigment. 
Hypomelanosis of Ito, linear nevoid hypopigmentation and nevus depigmentosus 
are considered to represent manifestations of cutaneous mosaicism.
Acquired diseases of depigmentation includes vitiligo, hypomelanosis second-
ary to cutaneous inflammation (postinflammatory hypopigmentation, pityriasis 
alba, sarcoidosis, hypopigmented mycosis fungoides, lupus erythematosus and 
lichen sclerosus et atrophicus), infectious hypomelanosis (tinea versicolor, 
leprosy, kala azar...), chemical or pharmacologic hypomelanosis (chemical leuko-
derma, hypomelanosis by strong steroid), hypomelanosis from physical agetnts 
(burn, laser, abrasion...), and miscellaneous (idiopathic guttate hypomelanosis, 
persistent macular hypomelanosis...) (Figure 2) [3].
Diseases of depigmentation can occur hereditarily or acquiredly. Hereditary 
diseases of depigmentation were reviewed excellently by Prof. Carrasquillo and 
colleagues. Albinism, piebaldism, white patches of tuberous sclerosis, Hermansky-
Pudlak syndrome, Chédiak-Higashi syndorme, Waardenburg syndrome, and 
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pigmentary mosaicism including hypomelanosis of Ito and nevus depigmentosus 
would be examples of them (Figure 1) [3].
Acquired diseases of depigmentation includes vitiligo, hypomelanosis second-
ary to cutaneous inflammation (postinflammatory hypopigmentation, pityriasis 
alba, sarcoidosis, hypopigmented mycosis fungoides, lupus erythematosus and 
lichen sclerosus et atrophicus), infectious hypomelanosis (tinea versicolor, 
leprosy, kala azar...), chemical or pharmacologic hypomelanosis (chemical leuko-
derma, hypomelanosis by strong steroid), hypomelanosis from physical agetnts 
(burn, laser, abrasion...), and miscellaneous (idiopathic guttate hypomelanosis, 
persistent macular hypomelanosis...) (Figure 2) [3].
Vitiligo is a common acquired disease of depigmentation, and afflicts and fright-
ens so many patients. In vitiligo, melanocytes that produces melanin pigment of 
the skin are destroyed, and it can occur systemically to affect whole body or locally/
segmentally affecting part of the body (Figure 2a and b) [3].
For the treatment of vitiligo, various lasers including 308 nm excimer laser are 
used successfully which has been used additionally with phototherapy and topical 
or systemic medications [5].
In patients with extensive vitiligo, depigmentation can be an easier and cosmeti-
cally more acceptable option. It includes various chemical and physical modalities. 
Figure 1. 
Hereditary diseases of depigmentation. a. White forelock of piebaldism. b. Piebaldism affecting legs.  
c. Linear nevoid hypopigmentation. d. Nevus depigmentosus.
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Figure 2. 
Acquired diseases of depigmentation. a. Systemic vitiligo affecting the whole body. b. Segmental vitiligo 
affecting one side of the body with white hairs (poliosis). c. Pityriasis alba, hypomelanosis secondary to 
cutaneous inflammation of atopic dermatitis. d. Hypomelanosis by tinea versicolor. e. Hypomelanosis by strong 
steroid (injection of triamcinolone acetonide). f. Hypomelanosis from physical injury induced by burn.  
g. Hypomelanosis from physical injury induced by abrasion wound. h. Idiopathic guttate hypomelanosis in 
older patients which belong to miscellaneous hypopigmentation.
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As in Figure 3a and b, depigmentation therapy can be an ideal treatment for 
advanced vitiligo patients. But cases presented in Figure 3c and d suggests restor-
ing normal pigmentation is also an excellent option, and it would be better to be 
decided by patient’s choice.
Cosmeceutical for depigmentation is a big market field for investigators and 
cosmetic companies. We have tragedic experiencies of chemical leukoderma and 
vitiligo induced by depegmentation cometics manufactured by Kanebo containing 
rhododendrol [6, 7]. Researchers put tremendous efforts to overcome it and there 
are a lot of active researches to find out newer materials for depigmentation [4, 7].
Figure 3. 
Depigmentation therapies for vitiligo. a. Systemic vitiligo patient before depigmentation therapy by 20% mono-
benzyl-ether of hydroquinone (MBEH). b. Systemic vitiligo patient after 6 months of depigmentation therapy 
by 20% MBEH. c. Systemic vitiligo patient before 308 nm excimer laser therapy. d. Systemic vitiligo patient 
after 6 months of 308 nm excimer laser therapy.
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